8-K: Entera Bio Expands OPKO Partnership, Advances Oral PTH Tablet

Entera Bio and OPKO Health expanded their collaboration to include a long-acting oral PTH tablet for hypoparathyroidism and appointed Steven D. Rubin to Entera's board.

Summary

• The collaboration with OPKO Health, Inc. and OPKO Biologics Ltd. (collectively, OPKO) has been amended and restated to expand its scope.
• The expanded agreement now includes the preclinical and clinical development of a daily long-acting PTH tablet (LA-PTH) for the treatment of hypoparathyroidism and other indications.
• Development costs for the LA-PTH program will be shared equally (50% by Entera and 50% by OPKO).
• The companies aim to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the oral LA-PTH tablet in late 2026.
• The original oral dual agonist GLP-1/glucagon peptide (Oxyntomodulin Analog) program continues with its previously announced 60% OPKO / 40% Entera cost-sharing arrangement.
• Initial Phase 1 data for the injectable oxyntomodulin (OXM) is expected in late 2026, with the oral OXM tablet formulation planned to enter the clinic thereafter.
• Gerald Ostrov resigned as a Director of Entera Bio Ltd., effective February 1, 2026, a resignation not attributed to any disagreement with the company.
• Steven D. Rubin, Executive Vice President Administration and a director at OPKO Health, was appointed as a Class III director to Entera's Board, effective February 1, 2026.
• Mr. Rubin will also serve as a member of the compensation committee and as Chairman of the audit committee of Entera's Board.
• OPKO Health holds 3,685,226 Entera Ordinary Shares, purchased in March 2025, with an $8,000,000 purchase price held in an escrow account.
• A standstill agreement prevents OPKO Health from acquiring more than 2% of Entera's voting equity until March 16, 2027, with a specific exception for Dr. Phillip Frost.
• A lock-up period on OPKO Health's existing Entera shares expires on March 16, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting strengthened partnership, expansion into a new promising indication with a potentially transformative oral therapy, and solid governance changes. However, it remains a preclinical/early clinical stage, high-risk venture with no immediate financial impact.

Positives

• The collaboration with OPKO Health has been expanded to include a new, promising program for a daily long-acting PTH tablet (LA-PTH) for hypoparathyroidism, addressing a significant unmet medical need.
• Favorable preclinical pharmacodynamic and pharmacokinetic (PK/PD) data for oral LA-PTH supports the acceleration of its development, with an IND filing targeted for late 2026.
• The equal (50/50) sharing of development costs for the LA-PTH program demonstrates a balanced commitment and shared risk between Entera and OPKO.
• The appointment of Steven D. Rubin, an experienced executive and director from OPKO Health, to Entera's Board, including as Chairman of the audit committee, strengthens corporate governance and strategic alignment.
• The oral oxyntomodulin (OXM) program for metabolic and fibrotic disorders is advancing, with initial Phase 1 data for the injectable formulation expected by late 2026, indicating continued pipeline progress.

Negatives

• The filing does not report any immediate financial gains or revenue, as it focuses on preclinical and early-stage clinical development and governance changes.
• The $8,000,000 purchase price for OPKO's shares remains in escrow, indicating a contingent financial arrangement rather than immediate cash flow.
• Entera's ability to continue as a going concern is explicitly mentioned as a risk factor in the forward-looking statements, highlighting potential liquidity challenges.
• The Opt-Out clause allows Entera to cease cost-sharing for a Collaboration Product, but doing so significantly reduces its share of future proceeds for that product to 15%, potentially limiting long-term upside.

Risks

• Changes in the interpretation of clinical data.
• Uncertainty regarding the results of clinical trials.
• The FDA's interpretation and review of clinical trial results.
• Unexpected changes in ongoing and planned preclinical development and clinical trials.
• The timing of and ability to make regulatory filings and obtain and maintain regulatory approvals for product candidates.
• Potential disruption and delay of manufacturing supply chains.
• Loss of available workforce resources, whether by Entera, OPKO, or their respective collaboration and laboratory partners.
• Impacts to research and development or clinical activities that Entera or OPKO may be contractually obligated to provide.
• Overall regulatory timelines.
• The size and growth of the potential markets for product candidates.
• The scope, progress, and costs of developing product candidates.
• Reliance on third parties to conduct clinical trials.
• Entera's and OPKO's expectations regarding licensing, business transactions, including OPKO's development efforts should Entera opt-out, and strategic collaborations.
• Entera's operation as a development stage company with limited operating history.
• Entera's ability to continue as a going concern absent access to sources of liquidity.
• Entera's ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States.
• Entera's and OPKO's intellectual property positions and their ability to protect their respective intellectual property.

Future Outlook

Entera Bio and OPKO Health are accelerating the development of the oral LA-PTH tablet, aiming for an IND filing in late 2026. Initial Phase 1 data for the injectable oxyntomodulin (OXM) is also expected by late 2026, with the oral OXM tablet formulation planned to enter the clinic thereafter. The collaboration seeks to provide more convenient, injection-free treatment options for hypoparathyroidism and advance therapies for metabolic and fibrotic disorders.

Management Comments

• "The partnership that our team has forged with OPKO since late 2023 has been very synergistic. Oral OXM and oral GLP-2 have both demonstrated robust PK profiles and bioavailability. Furthermore, preclinical data of oral LA-PTH suggests that this program holds the potential to transform the hypoparathyroidism landscape." Miranda Toledano, Chief Executive Officer of Entera.
• "I would also like to take this opportunity to thank Gerry Ostrov for his contributions and service at Entera, and to extend a warm welcome to Steve Rubin to our board of directors." Miranda Toledano, Chief Executive Officer of Entera.
• "We are pleased to expand our successful collaboration with Entera to advance this promising long-acting PTH program for hypoparathyroidism. This program builds on OPKO's expertise in developing differentiated long-acting peptides and Entera's innovative oral peptide platform. Our goal is to provide patients with hypoparathyroidism a more convenient treatment option that eliminates the burden of daily injections while maintaining therapeutic efficacy." Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO Health.

Industry Context

StockSavvy.ai notes that the expansion into an oral long-acting PTH tablet addresses a significant unmet need in the hypoparathyroidism market, where the only currently approved PTH replacement, Ascendis Pharma's YORVIPATH, requires daily injections. An oral, once-daily option could offer a substantial competitive advantage and improve patient quality of life. The advancement of the oral oxyntomodulin program also positions the companies in the rapidly evolving GLP-1/glucagon dual agonist space, a field with no currently approved dual agonists, indicating potential for market leadership in metabolic and fibrotic disorders.

Comparison to Industry Standards

• The current standard of care for PTH replacement therapy, YORVIPATH by Ascendis Pharma, requires daily injections. Investigational candidates typically require weekly injections. Entera and OPKO's oral LA-PTH aims for a once-daily tablet, representing a significant improvement in patient convenience compared to these injectable options.
• Entera's previous EB612 program (unmodified oral PTH(1-34)) required a four-times-daily (QID) regimen with doses up to 9mg daily. The new collaboration's preclinical data with OPKO's long-acting PTH variant supports a single, once-daily tablet at a significantly lower daily dose, indicating a substantial advancement over Entera's prior internal efforts.
• The GLP-1/glucagon dual agonist market currently has no approved products, positioning Entera and OPKO's oral oxyntomodulin as a potential first-in-class therapy if successful, contrasting with the crowded GLP-1 monotherapy market.

Management Changes

Corporate Governance

Related Party Transactions

• OPKO Health, Inc. (parent of OPKO Biologics Ltd.) purchased 3,685,226 Entera Ordinary Shares in March 2025, with the $8,000,000 purchase price held in escrow.
• Steven D. Rubin, an Executive Vice President and director at OPKO Health, was appointed to Entera's Board of Directors, including as Chairman of the audit committee and a member of the compensation committee.

Stakeholder Impact

• Shareholders: Potential for increased long-term value through an expanded pipeline and strengthened partnership, but also continued exposure to development-stage risks and potential dilution if Entera opts out of programs. The standstill and lock-up agreements provide some stability.
• Patients (Hypoparathyroidism): Potential for a more convenient, once-daily oral treatment option, eliminating the burden of daily injections.
• Patients (Metabolic/Fibrotic Disorders): Continued development of a potential first-in-class oral dual agonist GLP-1/glucagon peptide.
• Employees: Continued and expanded R&D activities, potentially leading to job stability and growth opportunities within the expanded programs.
• OPKO Health: Increased strategic alignment and potential for future revenue streams from the expanded collaboration, leveraging its long-acting peptide expertise.

Next Steps

• File an Investigational New Drug (IND) application with the FDA for the oral LA-PTH tablet in late 2026.
• Initiate a single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1 clinical study with the subcutaneous injection formulation of oxyntomodulin.
• Expect initial Phase 1 data from injectable oxyntomodulin (OXM) in late 2026.
• File an IND for the oral OXM tablet formulation after the injectable OXM enters the clinic.
• Entera and OPKO will continue to collaborate on the research and development of Collaboration Products under mutually agreed Development Plans.
• OPKO and Entera will negotiate Commercialization Terms if OPKO decides to directly commercialize a Collaboration Product.

Key Dates

Recommendation

The expanded collaboration with OPKO Health and the addition of a promising new oral LA-PTH program are positive developments for Entera Bio, indicating pipeline growth and continued strategic alignment. The appointment of an OPKO executive to the board further solidifies this partnership. However, the company remains in early-stage development with no immediate revenue, and significant clinical and regulatory hurdles lie ahead. The existing financial arrangement with OPKO, including the escrowed funds and the opt-out clause, introduces complexities. Given the long development timelines and inherent risks of biotech, a 'hold' recommendation is appropriate, awaiting further clinical data and clearer paths to commercialization.

Keywords

Entera Bio, OPKO Health, Collaboration Agreement, LA-PTH, Hypoparathyroidism, Oral Peptide, N-Tab Technology, Oxyntomodulin, GLP-1/Glucagon, Metabolic Disorders, Fibrotic Disorders, Drug Development, Clinical Trials, IND Filing, Biotechnology, Pharmaceuticals, Corporate Governance, Board Appointment, SEC Filing, ENTX, OPK